The Medicines Company revised earnings guidance for the year 2014. For the year, the company expects net revenue for 2014 will remain within the range of its previously announced guidance of $720 million to $735 million, but expects it to be at the lower end of that range.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+0.14% | -0.05% |
2020 | The Medicines Company Announces Board Changes | CI |
2020 | The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care | CI |
1st Jan change | Capi. | |
---|---|---|
-0.05% | 6.79B | |
+24.53% | 45.07B | |
+30.99% | 23.39B | |
+24.13% | 16.08B | |
+21.15% | 14.6B | |
+68.67% | 14.01B | |
-13.29% | 6.38B | |
-8.87% | 5.73B | |
+13.53% | 5.64B | |
+10.74% | 4.89B |
- Stock Market
- Equities
- MDCO Stock
- News The Medicines Company
- The Medicines Company Revises Earnings Guidance for the Year 2014